# Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

> **NCT04446117** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 575 (actual)

## Conditions studied

- Metastatic Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Atezolizumab
- **DRUG:** Abiraterone Acetate
- **DRUG:** Enzalutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04446117
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-19
- **Primary completion:** 2024-04-19
- **Final completion:** 2026-10-16
- **Target enrollment:** 575 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446117, "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04446117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*